Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention

Introduction

Only 13-28% of drug-treated type 2 diabetes patients receive insulin therapy. The late initiation of insulin reflects the general trend that it is a last resort therapy in the treatment of type 2 diabetes. Datamonitor believes that there will be a shift towards earlier initiation of insulin in the future, along with increased uptake, following the introduction of non-injected insulin. 

Scope

> Analysis of interviews with 388 physicians in the 7 major markets, validated via in-depth interviews with international experts

> Determination of the prevalence of type 1 and type 2 diabetes, with forecasts to 2012

> Analysis of the use of insulin therapy in the treatment of type 2 diabetes by line of therapy and evaluation of early vs. late initiation of insulin

> Assessment of the potential patient population for non-injected insulin: evaluation of switch from injected insulin and add-on to OAD therapy 

Highlights

Due to rising rates of obesity and the aging population, type 2 diabetes is an emerging epidemic: Datamonitor estimates there will be 50.1m diabetics in the seven major markets in 2012. Despite the large patient population, Datamonitor's physician research reveals that only 50% of type 2 diabetics across the seven major markets are diagnosed. 

The late initiation of insulin reflects the trend that insulin is a therapy of last resort in the treatment of type 2 diabetes. Although some experts believe that the earlier initiation of insulin is emerging, additional clinical trials are required to support this strategy. 

Non-injected insulins are expected to overcome the key unmet need in the insulin market by providing a more convenient mode of administration, and they are also expected to increase the overall use of insulin in type 2 diabetes patients and shorten the time to initiation.

Reasons to Purchase

> Understand the factors limiting the use of insulin in type 2 diabetes, based on both physician and patient perception

> Validate product forecasting based on diagnosis and treatment rates, and the estimated future use of insulin in the treatment of type 2 diabetes

> Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products 

Pages: 238 Published: May 2004 Format: PDF 

Publisher: Datamonitor Immune Disorders and Inflammation Rep. 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Immune_Disorders_and_Inflammation.html#a206